NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Laviana Pharma

Laviana Pharma

Private
TaizhouHealthcare & Life Scienceshttps://www.lavianacorp.com/

Last Round

Series C

Extension

Dec 27, 2022

Total Funding Raised

$121.7M

Company Overview

Laviana Pharma is a contract development and manufacturing organization (CDMO) company that provides a one-stop service platform for small-molecule innovative drugs, from process research and development to commercial manufacturing.

Sector

Healthcare & Life Sciences

Verticals

Pharma Supply Chain, Clinical Trials, Biotechnology, Drug Discovery, Clean Manufacturing

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CDMOsmall-molecule CDMOcontract development and manufacturing organizationsmall-molecule drugsAPI manufacturingCMC servicesprocess R&Dintermediate manufacturingcustom synthesisGMP-compliant manufacturingpharma outsourcingformulation researchchemistry, manufacturing, and controlsIND submission supportNDA submission supportgreen chemistry

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Laviana Pharma Comps

Public and private peers based on sector, stage, and business model.

Laviana Pharma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Laviana Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionDec 27, 2022
Series COct 13, 2021
Series B ExtensionSep 2, 2019
Series BApr 18, 2018

Key People

Founding team and executive leadership

邓国璇

CTO

Executive Team

Laviana Pharma Investors

Notable investors and investment history

Laviana Pharma investors
InvestorRounds
V-CapitalSeries B Extension
Puhua CapitalSeries C
Shanghai Shiyue Asset ManagementSeries C
Shenzhen Yifeng Investment Management EnterpriseSeries C Extension
Huayi CapitalSeries C, Series B
LanTing CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 20, 2026

    Monthly visitors grew 136% MoM.

  • Jul 6, 2025

    Monthly visitors grew 6938% MoM, from 8 to 563.

Laviana Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Laviana Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Laviana Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersTaizhou
Employee Range30
Year Founded2003
Last FundingDec 27, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.